Retro Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Retro Biosciences, Inc. - overview
Established
2021
Location
Redwood City, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2021, Retro Biosciences, Inc. , d. b. a.
Retro develops therapies primarily for diseases related to aging and adds more years to the human lifespan. The company was co-founded by Joe Betts-LaCroix (CEO), Matt Buckley, and Sheng Ding, and in January 2025, Retro Biosciences, Inc. raised USD 1 billion in series A funding led by an individual investor, with participation from another individual investor. Retro Biosciences provides cellular reprogramming, autophagy, and plasma-inspired therapeutics to increase a healthy human lifespan.
The company plans the January 2025 funding to accelerate its research and development.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.retro.bio
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.